Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

被引：12
作者：
Chan, Onyee [1 ,2 ]
Hunter, Anthony [1 ,2 ]
Talati, Chetasi [1 ]
Sallman, David A. [1 ,3 ]
Asghari, Hannah [1 ,2 ]
Song, Jinming [4 ]
Hussaini, Mohammad [4 ]
Bejanyan, Nelli [5 ]
Elmariah, Hany [5 ]
Kuykendall, Andrew T. [1 ]
Padron, Eric [2 ]
Komrokji, Rami S. [1 ,3 ,6 ]
List, Alan F. [1 ]
Lancet, Jeffrey E. [1 ]
Sweet, Kendra L. [1 ]
Mishra, Asmita [5 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Div Malignant Hematol, Tampa, FL USA
[2] Univ S Florida, Dept Med, Tampa, FL 33620 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat & Cellular Immun, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Div Malignant Hematol, Tampa, FL USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131530
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
149
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Impact of TP53 Allelic State on Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasm
    Jiang, Bingqian
    Yang, Tingting
    Luo, Yi
    Zhao, Yanmin
    Ouyang, Guifang
    Yu, Jian
    Lan, Jianping
    Lu, Ying
    Lai, Xiaoyu
    Ye, Baodong
    Chen, Yi
    Liu, Lizhen
    Xu, Yang
    Shi, Pengfei
    Xiao, Haowen
    Hu, Huixian
    Guo, Qunyi
    Fu, Huarui
    Ye, Yishan
    Wang, Xinyu
    Sun, Jie
    Zheng, Weiyan
    He, Jingsong
    Zhao, Yi
    Wu, Wenjun
    Cai, Zhen
    Wei, Guoqing
    Huang, He
    Shi, Jimin
    BLOOD, 2023, 142
  • [32] Phase II Trial of Reduced Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL
    Chen, Yi-Bin
    Li, Shuli
    Del Rio, Candice
    Coughlin, Erin
    Ballen, Karen K.
    Cutler, Corey S.
    Dey, Bimalangshu R.
    Ho, Vincent T.
    McAfee, Steven L.
    Spitzer, Thomas R.
    Alyea, Edwin P., III
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S217 - S218
  • [33] TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation
    Middeke, Jan M.
    Herold, Sylvia
    Ruecker-Braun, Elke
    Berdel, Wolfgang E.
    Stelljes, Matthias
    Kaufmann, Martin
    Schaefer-Eckart, Kerstin
    Baldus, Claudia D.
    Stuhlmann, Reingard
    Ho, Anthony D.
    Einsele, Hermann
    Roesler, Wolf
    Serve, Hubert
    Haenel, Mathias
    Sohlbach, Kristina
    Klesse, Christian
    Mohr, Brigitte
    Heidenreich, Falk
    Stoelzel, Friedrich
    Roellig, Christoph
    Platzbecker, Uwe
    Ehninger, Gerhard
    Bornhaeuser, Martin
    Thiede, Christian
    Schetelig, Johannes
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (06) : 914 - 922
  • [34] Allogeneic Stem Cell Transplantation with Myeloablative Compared with Reduced-Intensity Conditioning for AML and Mds; 20 Years Later
    Shimoni, Avichai
    Yerushalmi, Ronit
    Shem-Tov, Noga
    Danylesko, Ivetta
    Avigdor, Abraham
    Nagler, Arnon
    BLOOD, 2023, 142
  • [35] Allogeneic Stem Cell Transplantation Overcomes the Negative Prognostic Impact of TP53 Alterations in Mantle Cell Lymphoma
    Lin, Richard J.
    Ho, Caleb
    Hilden, Patrick
    Barker, Juliet
    Giralt, Sergio
    Hamlin, Paul A.
    Jakubowski, Ann A.
    Castro-Malaspina, H. R.
    Papadopoulos, Esperanza B.
    Perales, Miguel-Angel
    Sauter, Craig S.
    BLOOD, 2018, 132
  • [36] Reduced Intensity Conditioning in Allogeneic Stem Cell Transplantation for AML With Down Syndrome
    Muramatsu, Hideki
    Sakaguchi, Hirotoshi
    Taga, Takashi
    Tabuchi, Ken
    Adachi, Souichi
    Inoue, Masami
    Kitoh, Toshiyuki
    Suminoe, Aiko
    Yabe, Hiromasa
    Azuma, Eichi
    Shioda, Yoko
    Ogawa, Atsushi
    Kinoshita, Akitoshi
    Kigasawa, Hisato
    Osugi, Yuko
    Koike, Kazutoshi
    Kawa, Keisei
    Kato, Koji
    Atsuta, Yoshiko
    Kudo, Kazuko
    PEDIATRIC BLOOD & CANCER, 2014, 61 (05) : 925 - 927
  • [37] TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome
    Kim, Yoo-Jin
    Jung, Seung-Hyun
    Hur, Eun-Hye
    Choi, Eun-Ji
    Lee, Kyoo-Hyung
    Yim, Seon-Hee
    Kim, Hye-Jung
    Kwon, Yong-Rim
    Jeon, Young-Woo
    Lee, Sug Hyung
    Chung, Yeun-Jun
    Lee, Je-Hwan
    LEUKEMIA RESEARCH, 2018, 74 : 97 - 104
  • [38] TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome
    Kim, Yoo-Jin
    Jung, Seung-Hyun
    Hur, Eun-Hye
    Choi, Eun-Ji
    Lee, Kyoo-Hyung
    Yim, Seon-Hee
    Kim, Hye-Jung
    Kwon, Yong-Rim
    Jeon, Young-Woo
    Lee, Sug Hyung
    Chung, Yeun-Jun
    Lee, Je-Hwan
    BONE MARROW TRANSPLANTATION, 2018, 53 : 667 - 668
  • [39] Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients
    Berning, Philipp
    Kolloch, Lina
    Reicherts, Christian
    Call, Simon
    Marx, Julia
    Floeth, Matthias
    Esseling, Eva
    Ronnacker, Julian
    Albring, Joern
    Schliemann, Christoph
    Lenz, Georg
    Stelljes, Matthias
    BONE MARROW TRANSPLANTATION, 2024, 59 (08) : 1097 - 1106
  • [40] Obesity does not impact outcome in patients with AML/MDS undergoing allogeneic transplantation
    De Padua Silva, Leandro
    Saliba, Rima. M.
    de Lima, Marcos
    Okoroji, Grace J.
    Alousi, Athin
    Andersson, Borje
    Hosing, Chitra
    Sphall, Elizabeth
    Khuri, Issa
    Qazilbash, Muzaffar
    Anderlini, Paolo
    Kebriaei, Partow
    Champlin, Richard E.
    Jones, Roy
    Biralt, Sergio
    Popat, Uday
    BLOOD, 2007, 110 (11) : 592A - 592A
12345